XNAS · IDYA
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
IDEAYA Biosciences, Inc. Common Stock

IDEAYA Biosciences, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$39.67
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
IDYA
IDEAYA Biosciences, Inc. Common Stock
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

83/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is IDYA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading IDYA catalysts
About IDEAYA Biosciences, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2019
Employees
145
Country
US

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$39.67
Last session
Day high
$39.67
Last session
Day low
$39.67
Last session
Previous close
$39.67
52W high
$40.51
-2.07% from high
52W low
$23.39
95% of range
Market cap
$3.8B
EPS
$-1.8800
Beta
0.84
Shares out
96.5M
Avg volume
755.5K
VWAP
$39.67
Last session
Price history computed in-house
1W
+8.57%
1M
+12.06%
3M
+35.16%
1Y
+57.92%
YTD
+14.75%
SMA 50 $35.91 · above
SMA 200 $33.26 · above
52W position 95%

IDYA overview

Veridion Score
83
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around IDYA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading IDYA Form 4 filings
Public disclosures

Congress activity in IDYA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for IDYA in the cached public ledger.

Federal contracts

IDYA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IDYA in this window.
Lobbying spend

IDYA lobbying filings, year to date.

Registered lobbying filings matched to IDEAYA Biosciences, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IDYA in this window.
Loading news for IDYA
Analyst ratings
Sovereign unlock shows live analyst consensus for IDYA.
Options
Sovereign unlock shows live options positioning for IDYA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.